Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats

Clinical and Experimental Hypertension

Volumn 30, Issue 2, 2008, Pages 159-169

  Peredo, H A ^a,b   Mayer, M A ^a   Carranza, A ^a   Puyo A M ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b NONE   (Argentina)

Author keywords

Fructose; Hypertension; Losartan; Pioglitazone; Prostanoids; Triglycerides

Indexed keywords

FRUCTOSE; LOSARTAN; PIOGLITAZONE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA FLOW; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; HEART HEMODYNAMICS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; MESENTERY BLOOD FLOW; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; RAT; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOOD PRESSURE; BLOOD VESSELS; DINOPROSTONE; DRUG SYNERGISM; EPOPROSTENOL; FRUCTOSE; HEMODYNAMICS; LOSARTAN; MALE; MESENTERY; PPAR GAMMA; PROSTAGLANDINS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; THROMBOXANES; TRIGLYCERIDES;

EID: 39749180264     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960801946889     Document Type: Article

References (43)

1. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988;37:1597-1607.
2. Hwang Y, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987;10:512-516.
3. Preuss HG, El Zein M, Knapka J, Macarthy P, Yousufi AK, Gleim GW, Glace B, Zukowska-Grojec Z. Blood pressure responses to sucrose ingestion in four rat strains. Am J Hypertension. 1992;5:244-250.
4. Chicco A, Soria A, Fainstein-Day P, Gutman RA, Lombardo YB. Multiphasic metabolic changes in the heart of rats fed a sucrose-rich diet. Horm Metab Res. 1994;26:397-403.
5. Verma S, Bhanot S, Yao J, McNeill JH. Defective endothelium-dependent relaxation in fructose-hypertensive rats. Am J Hypertension. 1996;9:370-376.
6. Damiano PF, Cavallero S, Mayer M, Rosón MI, de la Riva I, Fernández B, Puyó AM. Impaired response to insulin associated to protein kinase C in chronic fructose-induced hypertension. Blood Pres. 2002;11:345-351.
7. Peredo HA. Prostanoid release and constrictor responses to noradrenaline in the mesenteric vascular bed in non-insulin-dependent diabetes mellitus. J Auton Pharmacol. 2001;21:131-137.
8. Galipeau D, Arikawa E, Sokivov J, McNeill SH. Chronic thromboxane synthase inhibition prevents fructose-fed hypertension. Hypertension. 2001;38:872-876.
9. González-Ortiz M, Martínez-Abundis E, Balcázar- Muñoz BR, Robles-Cervantes JA. A COX-2 selective, but not ASA, an inspecific COX inhibitor, increased insulin sensitivity in healthy subjects. Horm Metab Res. 2001;33:250-253.
10. Peredo HA, Enero MA. Effect of endothelium removal on basal and muscarinic cholinergic stimulated rat mesenteric vascular bed prostanoid synthesis. Prostaglandins Leukot Essent Fatty Acids. 1993;48:373-378.
11. Peredo HA, Feleder EC, Adler-Graschinsky E. Differential effects of acetylcholine and bradykinin on prostanoid release from the rat mesenteric bed: role of endothelium and nitric oxide. Prostaglandins Leukot Essent Fatty Acids. 1997;56:253-258.
12. Peredo HA, Adler-Graschinsky E. Effects of eicosanoids and nitric oxide on the noradrenaline-induced contractions in the rat mesenteric bed. J Auton Pharmacol. 2000;20:163-170.
13. Peredo HA. Opposite effects of endogenous nitric oxide and prostaglandin F2 alpha in the rat mesenteric bed. Auton Autacoid Pharmacol. 2003;23:167-172.
14. Puyó AM, Mayer MA, Cavallero S, Donoso AS, Peredo HA. Fructose overload modifies vascular morphology and prostaglandin production in rats. Auton Autacoid Pharmacol. 2004;24:29-35.
15. Navarro-Cid J, Maeso R, Pérez-Vizcaíno F, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V. Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension. 1995;26:1074-1078.
16. Miyazaki Y, Glass I, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type 2 diabetic patients. Diabetologia. 2001;44:2210-2219.
17. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172-178.
18. Miatello R, Risler N, Castro C, Cruzado M, González S, Zumino AP. Chronic administration of losartan reverses cardiovascular changes in hypertensive fructosa-fed rats. Cell Mol Biol. 2003;49:945-952.
19. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the rennin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension. 2004;43:255-262.
20. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interactions of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism. 2005;54:157-164.
21. Inoue, I, Takahashi K, Katayama S, Harada Y, Negishi K, Itabashi A, Ishii J. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism. 1995;44:1616-1626.
22. Chen CC, Wang HJ, Shih HC, Sheen LY, Chang CT, Chen RH, Wang TY. Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. J Formos Med Assoc. 2001;100:176-180.
23. + exchanger in fructose-fed borderline hypertensive rats. Hypertens Res. 2003;26:111-116.
24. St-Pierre P, Bouffard L, Maheux P. Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. Biochem Pharmacol. 2004;67:1997-2004.
25. Oron-Herman M, Sela B-A, Rosenthal T. Risk reduction therapy for syndrome X: Comparison of several treatments. Am J Hypertens. 2005;18:372-378.
26. Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A. Effect of PPAR-γ?agonist on adiponectin levels in the metabolic syndrome: Lessons from the high fructose fed rat model. Am J Hypertens. 2007;20:2006-2010.
27. Chakir M, Plante GE, Maheux P. Reduction of capillary permeability in fructose-induced hypertensive rat. Am J Hypertens. 1998;11:563-569.
28. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Oishi M, Sujimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsusawa Y, Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-1323.
29. Ohashi K, Kihara S, Ouchi N, Kamada M, Fujita K, Hinge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funabashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47:1108-1116.
30. Unger RH. Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003;14:398-403.
31. Chicco A, Basabe JC, Karabatas L, Ferraris N, Fortino A, Lombardo YB. Troglitazone (CS-045) normalizes hypertriglyceridemia and restores the altered patterns of glucose-stimulated insulin secretion in dyslipidemic rats. Metabolism. 2000;49:1346-1351.
32. Carpentier S, Changiz TM, Leung N, Szeto L, Van Iderstine SC, Uffelman KD, Buckingham R, Khosrow A, Lewis GF. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in fructose-fed hamster. J Biol Chem. 2002;277:28795-28802.
33. Peredo HA, Mayer MA, Rodríguez Fermepín M, Grinspon D, Puyó AM. Oral treatment and in vitro incubation with fructose modify vascular prostanoid production in the rat. Auton Autacoid Pharmacol. 2006;26:15-20.
34. 2 synthesis. Thorax. 2006;61:604-610.
35. De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Bianchi M, Berti F, Muller EE, Rossoni G. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol. 2005;15:253-259.
36. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens. 1991;4 (Suppl. 3):228-233.
37. Bayorth MA, Ganafa AA, Socci RR, Eatman D, Silvestrov N. Abukhalaf IK. Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. Am J Hypertens. 2003;16:387-392.
38. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, Lo MW, McWilliams EJ, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
39. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides: Characterization of receptors. Hypertension. 1992;19 (Suppl. 2):49-55.
40. Fujiwara T, Oshawa T, Takahashi S, Ikeda K, Okuno A, Ushiyama S, Matsuda K, Horikoshi H. Troglitazone, a new antidiabetic agent possessing radical scavenger ability, improved decreased skin blood flow in diabetic rats. Life Sci. 1998;63:2039-2047.
41. Hishinuma T, Yamazaki T, Mizugaki M. Troglitazone has a reducing effect on thromboxane production. Prostaglandin Other Lipid Mediat. 2000;62:135-143.
42. Ikeda Y, Sugawara A, Taniyama Y, Uruno A, Igarashi K, Arima S, Ito S, Takeuchi K. Supression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem. 2000;20:33142-33150.
43. Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement on hypertension and insulin resistance. Diabetes. 2006;55:3594-3603.